COPD的CT影像与合并症:超越肺癌筛查
本文综述了COPD患者合并症的负担及胸部CT影像作为合并症替代标志物的研究证据,探讨在肺癌筛查时代如何利用CT识别高风险合并症患者,并指出指南缺乏筛查指导、全面筛查可能不具成本效益,而靶向早期筛查可能改善结局。
要点
- COPD合并症显著增加发病率、死亡率和医疗费用,且风险常独立于吸烟等共同危险因素。
- 指南认可管理合并症的重要性,但缺乏最佳筛查实践的指导。
- 胸部CT的某些影像特征可能作为COPD合并症的替代标志物,助识别高危患者。
核心结论
- COPD患者合并症负担重且常独立于肺病严重程度和吸烟等共同危险因素。
- 指南缺乏合并症筛查指导,全面筛查可能不具成本效益。
- 胸部CT影像特征可能作为合并症替代标志物,助靶向早期筛查高危患者。
研究设计与样本
- 综述类文章,评估胸部CT影像特征作为COPD合并症替代标志物的相关研究。
主要发现
- COPD合并症患病率并不总是与肺病严重程度相关。
- 某些合并症风险升高常独立于烟草负担等共同危险因素。
- 近期研究表明胸部CT某些影像特征可能作为COPD合并症的替代标志物。
临床怎么用
- 在肺癌筛查中利用胸部CT识别COPD合并症高危患者,进行靶向早期筛查和治疗。
- 避免对全部COPD患者进行无差别的合并症筛查,因可能不具成本效益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Comorbidities significantly contribute to morbidity, mortality, and health-care costs in individuals with COPD. Comorbidity prevalence does not always correlate with lung disease severity, and the elevated risk of certain comorbidities is often independent of shared risk factors such as tobacco burden. Although COPD management guidelines recognize the importance of identifying and treating comorbidities as part of the comprehensive management of COPD patients, little guidance is provided regarding best screening practices. Whereas universal comorbidity screening in COPD patients is likely not cost-effective, targeted early screening and treatment in those at highest risk may have a significant impact on COPD outcomes. Recent studies suggest that certain radiographic features on thoracic imaging may serve as surrogate markers of comorbidity in patients with COPD. This review evaluates these studies in the context of the growing availability of chest CT scans in the lung cancer screening era and discusses how chest CT imaging can be leveraged to identify those COPD patients at highest risk for comorbid disease.
引用
- Singhvi D, Bon J. CT Imaging and Comorbidities in COPD: Beyond Lung Cancer Screening. Chest. 2020. PMID: 32835707. doi:10.1016/j.chest.2020.08.2053
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。